Cabozantinibin in patient with metastatic renal cell carcinoma with extensive skeletal involment

Simple item page
dc.contributor.authorRichter Igorcs
dc.contributor.authorDvořák Josefcs
dc.date.accessioned2020-06-08T09:51:45Z
dc.date.available05-18-2020en
dc.date.available2020-06-08T09:51:45Z
dc.date.issued2019cs
dc.date.updated05-19-2020en
dc.format.extent2cs
dc.identifier.issn1801-1209cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/156818
dc.language.isoczecs
dc.publisherFarmakon Presscs
dc.publisher.cityPrahacs
dc.relation.ispartofFarmakoterapieen
dc.relation.ispartofseries0cs
dc.subjectmetastatic renal cell carcinomacs
dc.subjecttargeted treatmentcs
dc.subjectimmunotherapycs
dc.subjectlong-term response ratecs
dc.subjectcabozantinibcs
dc.titleCabozantinibin in patient with metastatic renal cell carcinoma with extensive skeletal involmenten
dc.titleKabozantinib u pacienta s mRCC s výrazným postižením skeletucs
local.citation.epage47-48cs
local.citation.spage47-48cs
local.identifier.publikace7647
local.relation.issue3cs
Files
Collections